Last 43 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 20.86 | 8.95 | 3.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +460.5% | +522.0% | -13.6% | |
| P/B Ratio | 0.03 | 0.42 | — | 20.38 | 1.18 | 0.63 | 0.60 | 0.61 | 0.49 | 0.41 | 0.48 | 0.83 | 0.33 | 0.66 | 0.37 | 0.55 | 0.58 | 1.08 | 1.04 | 0.93 | 0.86 |
| — | -34.4% | — | +3236.9% | +141.9% | +55.6% | +25.4% | -26.1% | +45.8% | -38.5% | +31.8% | +49.1% | -42.6% | -38.4% | -64.8% | -40.6% | -32.2% | +45.6% | -5.3% | +157.1% | -41.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | — | 0.0% | 0.0% | 0.0% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 225.2% | — | -545.5% | -142.2% | -118.9% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +289.5% | — | -293.9% | +32.0% | +40.1% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 223.1% | — | -538.1% | -146.0% | -119.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +286.6% | — | -274.9% | +20.7% | +34.1% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.0% | -51.1% | — | -217.3% | -66.0% | -36.7% | -47.3% | -38.4% | -15.5% | -33.7% | -55.5% | -67.0% | -47.2% | -60.7% | -14.7% | -16.9% | -10.1% | -8.4% | -6.5% | -5.2% | -8.3% |
| — | -39.3% | — | -466.0% | -325.5% | -8.9% | +14.8% | +42.7% | +67.1% | +44.5% | -278.2% | -295.6% | -367.8% | -618.5% | -125.9% | -224.4% | -22.0% | +7.9% | +36.5% | +64.2% | +55.4% | |
| ROA | -116.0% | -23.3% | -51.3% | -63.8% | -42.5% | -26.2% | -33.8% | -29.9% | -11.8% | -23.9% | -35.1% | -43.2% | -37.1% | -54.0% | -13.6% | -16.0% | -9.6% | -8.2% | -6.3% | -4.9% | -7.4% |
| — | +11.1% | -52.0% | -113.2% | -261.6% | -9.8% | +3.7% | +30.8% | +68.3% | +55.8% | -157.0% | -170.1% | -284.2% | -562.2% | -117.8% | -227.1% | -31.0% | +1.1% | +32.2% | +60.1% | +44.5% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | -105.0% | -40.9% | -49.0% | -30.7% | -23.9% | -18.6% | -11.3% | -11.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -339.5% | -119.7% | -332.1% | -171.6% | -94.2% | -31.4% | +49.1% | +49.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | — | — | 1.81 | 0.15 | 0.11 | — | 0.03 | 0.05 | 0.08 | — | — | — | — | — | — | — | — | — | 0.00 | 0.02 |
| — | — | — | +5565.6% | +167.9% | +49.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | -72.0% | -54.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.98 | 5.49 | 0.92 | 1.01 | 1.98 | 4.09 | 2.98 | 3.91 | 5.02 | 3.59 | 3.28 | 2.21 | 3.40 | 5.78 | 8.31 | 11.88 | 14.29 | 21.82 | 24.66 | 20.94 | 5.70 |
| — | +34.3% | -69.2% | -74.1% | -60.6% | +14.0% | -9.2% | +77.0% | +47.4% | -37.9% | -60.5% | -81.4% | -76.2% | -73.5% | -66.3% | -43.3% | +150.9% | +285.2% | +347.8% | +296.8% | +302.0% | |
| Quick Ratio | 1.98 | 5.49 | 0.92 | 1.01 | 1.98 | 4.09 | 2.98 | 3.91 | 5.02 | 3.59 | 3.28 | 2.33 | 3.40 | 5.78 | 8.31 | 11.88 | 14.29 | 21.82 | 24.73 | 20.94 | 5.70 |
| — | +34.3% | -69.2% | -74.1% | -60.6% | +14.0% | -9.2% | +68.2% | +47.4% | -37.9% | -60.5% | -80.4% | -76.2% | -73.5% | -66.4% | -43.3% | +150.9% | +285.2% | +349.1% | +296.8% | +302.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1447.15 | -629.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLRX stock.
Salarius Pharmaceuticals, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Salarius Pharmaceuticals, Inc.'s business trajectory between earnings reports.